The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

DOI: 10.1371/journal.pone.0175207

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text